Q BioMed Inc. (QBIO)

OTCMKTS: QBIO · Delayed Price · USD
0.115
0.005 (4.55%)
May 16, 2022 4:00 PM - Market closed
Market Cap3.61M
Revenue (ttm)270,656
Net Income (ttm)-8.05M
Shares Out31.43M
EPS (ttm)-0.31
PE Ration/a
Forward PE109.89
Dividendn/a
Ex-Dividend Daten/a
Volume153,838
Open0.120
Previous Close0.110
Day's Range0.105 - 0.130
52-Week Range0.105 - 1.060
Beta1.71
AnalystsBuy
Price Target6.12 (+5,221.7%)
Earnings Daten/a

About QBIO

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B for liver cancer. Q BioMed Inc. has a partnership wi...

IndustryBiotechnology
Founded2013
Employees3
Stock ExchangeOTCMKTS
Ticker SymbolQBIO
Full Company Profile

Analyst Forecast

According to 7 analysts, the average rating for QBIO stock is "Buy." The 12-month stock price forecast is 6.12, which is an increase of 5,221.74% from the latest price.

Price Target
$6.12
(5,221.74% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Q BioMed Outlines Strategy and Value Proposition in Multi-Billion Dollar Markets

Management's assessment and value of Q BioMed outlined NEW YORK , May 6, 2022 /PRNewswire/ -- Q BioMed, Inc. (OTCQB: QBIO) a commercial-stage biotechnology development company outlines its strategy and ...

1 week ago - PRNewsWire

Q BioMed announces publication of research showing augmented efficacy of its drug candidate Uttroside-B against liver...

NEW YORK , March 16, 2022 /PRNewswire/ -- Q BioMed, Inc. (OTCQB: QBIO) a commercial-stage biotechnology development company announces a new publication supporting the efficacy and further development of...

2 months ago - PRNewsWire

Q BioMed Announces Initial $500k Order of Strontium89 to Chinese Market

NEW YORK, March 7, 2022 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has received a confirmed $500,000 order for Strontium Chloride USP Inject...

2 months ago - PRNewsWire

Q BioMed Outlines Strategic Direction for 2022

NEW YORK, Feb. 14, 2022 /PRNewswire/ -- Q BioMed Inc.  (OTCQB: QBIO), a biomedical acceleration and development company, focused on licensing, acquiring, and monetizing life science assets, outlines str...

3 months ago - PRNewsWire

Q BioMed Shows Significant Uptrend in Revenues in Year-End Update

NEW YORK, Dec. 16, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB:  QBIO ), a commercial-stage biotech company, provides this update to shareholders with positive trend in revenues, advancement in pipeline a...

5 months ago - PRNewsWire

Q BioMed Inc. Provides Shareholder Update

NEW YORK, Oct. 25, 2021 /PRNewswire/ --  Q BioMed Inc. (OTCQB: QBIO), a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthca...

6 months ago - PRNewsWire

Q BioMed Inc. Provides Update on Strontium89 Commercial Roll Out Revenue Up in 4th Quarter with Positive Trend

NEW YORK, Sept. 28, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO) a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthcar...

7 months ago - PRNewsWire

Q BioMed Inc. Updates on COVID-19 Therapeutic Development and Clinical Trials - MAN-19 therapeutic program heading to...

NEW YORK, Sept. 22, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO) a commercial stage biotechnology acceleration company, is pleased to provide an update on its partner asset MAN-19 for the treatment ...

7 months ago - PRNewsWire

Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Notice of Allowance for Patent in South Korea and Shows Promisin...

NEW YORK, Aug. 24, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO) a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthcare...

8 months ago - PRNewsWire

Q BioMed Signs Distribution Agreement with isoSolutions for the Sales of Strontium89 in Canada

NEW YORK, Aug. 10, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has recently entered into an exclusive distribution agreement with isoSol...

9 months ago - PRNewsWire

Q BioMed Signs License Agreement with Clionix for the Distribution and Sales of Strontium89 in Europe and Middle East

NEW YORK, July 12, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has recently entered into an exclusive license agreement with Clionix, a ...

10 months ago - PRNewsWire

Q BioMed Inc. Discusses Progress of COVID-19 Therapeutic and $30 Million Potential Investment with The Stock Day Podcast

Phoenix, Arizona--(Newsfile Corp. - June 23, 2021) - The Stock Day Podcast welcomed Q BioMed Inc. (OTCQB: QBIO) ("the Company"), a biotech acceleration and commercial stage company. CEO of the Company, ...

10 months ago - Newsfile Corp

Q BioMed Engages Contract Sales Force with Deep VA and Oncology Experience

NEW YORK, May 20, 2021 /PRNewswire/ --  Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has hired WSI PBG, LLC (WSI), a Michigan based firm specializing in creat...

11 months ago - PRNewsWire

Q BioMed Insider to Invest up to $30M in the Company

NEW YORK, May 11, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB:  QBIO ), announced today that it has signed a securities purchase agreement ("Transaction") with Aedesius Holdings Ltd (AedesiusOne), a priva...

1 year ago - PRNewsWire

Q BioMed Updates Shareholders

NEW YORK, April 27, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, updates shareholders. In March 2021,it was announced that our technology partner, Mannin Researc...

1 year ago - PRNewsWire

Q BioMed Awarded Federal Supply Contract for Strontium89 with U.S. Department of Defense and Veterans Affairs

NEW YORK, March 2, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has signed an agreement for Strontium89 (Strontium Chloride Sr-89 Injecti...

1 year ago - PRNewsWire

Q BioMed Expands Strontium89 Reach Through Agreement with UroGPO, the Largest Group Purchasing Organization for Indep...

NEW YORK, Feb. 1, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has been awarded a contract with UroGPO, the largest Group Purchasing Orga...

1 year ago - PRNewsWire

Q BioMed's Uttroside-B Receives U.S. FDA Orphan Drug Designation in the Treatment of Liver Cancer

NEW YORK, Jan. 27, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), announced today that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted Orphan Drug Designatio...

1 year ago - PRNewsWire

Q BioMed Updates Shareholders at Year End

NEW YORK, Dec. 29, 2020 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, today issued a letter to shareholders. Dear Fellow Shareholders, As 2020 draws to a close, we joi...

1 year ago - PRNewsWire

Q BioMed Technology Partner Mannin Research Inc. Announced as Member of Canadian National COVID-19 Consortium

NEW YORK, Dec. 21, 2020 /PRNewswire/ -- Q BioMed, Inc. (OTCQB: QBIO) is pleased to announce that its technology partner Mannin Research Inc. (MRI), a private Canadian biotechnology company, is a member ...

1 year ago - PRNewsWire